Francesca Fontana

speaker

2,691 appearances 52 recordings 1 series first heard Aug 2017 last heard Feb 2025

Francesca Fontana’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

No recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.

Appearances

newest first · ▶ plays the moment

WSJ Your Money Briefing · What’s News in Markets: Banking Boom, Macy’s Troubles, Drugmakers Slide · 18 Jan 2025 podcast

Not all retailers had a holly jolly holiday season in 2024.

Now, that's not to say shoppers weren't busy.

They were, and I have data to prove it.

During November and December, core retail sales increased 4% from 2023, per the Commerce Department.

But some companies didn't get as much demand as they expected.

For instance, Macy's.

So on Monday, the department store chain warned of weaker holiday sales, despite the company's recent efforts to boost revenue and turn the company around.

Macy's shares tumbled 8.1% Monday and on a weekly basis lost more than 11%.

Meanwhile, Target had good holiday sales, but you wouldn't know that from its stock move on Thursday.

After years of sluggish sales, the big-box giant reported better-than-expected sales in the all-important holiday period.

But even so, Target shares slipped 1% Thursday and, on a weekly basis, fell 5.7%.

Last but not least, it wasn't just me who was under the weather this week.

So were some of the big names in drugmaker stocks.

Now let's start with Moderna, whose shares took a nosedive after its latest earnings report.

Notably, the biotech company's 2025 revenue guidance missed Wall Street's expectations.

And Moderna really slashed this forecast.

Before, the company had predicted full-year revenue of up to $3.5 billion.

Now it predicts $1.5 to $2.5 billion, as sales of its COVID and RSV vaccines remain sluggish.

Shares plunged 17% on Monday, and on a weekly basis, the stock lost 19%.

Then there was Eli Lilly, which on Tuesday warned that sales of its popular diabetes and anti-obesity drugs, Mount Jaro and Zetbound, were growing slower than anticipated, citing the lower-than-expected inventory of the drugs.

Showing 221–240 of 2,691 · page 12 of 135